Mini-dose glucagon may prevent exercise-associated hypoglycemia in patients with type 1 diabetes
Canada: Mini-dose glucagon with or without a 50% reduction in CSII (continuous subcutaneous insulin infusion) basal delivery rate may decrease exercise-associated hypoglycemia (EAH) incidence in patients with type 1 diabetes, says a recent study. The study's findings appeared in the journal Diabetes Care on January 23 2023.
Glucagon is the standard of care for hypoglycaemia treatment. Ronnie Aronson from LMC Diabetes & Endocrinology in Toronto, Ontario, Canada, and colleagues aimed to determine the effect of ready-to-use, mini-dose glucagon on the incidence of exercise-associated hypoglycemia in adults with type 1 diabetes.
The patients initially participated in the in-clinic training phase for which they were randomly allocated to 150 µg glucagon labelled as treatment arm A or placebo labelled as arm B subcutaneously in a crossover design immediately before exercise, plus a 50% reduction in continuous SC insulin infusion basal delivery rate. Then the completers were randomly assigned in the outpatient investigational phase of 12 weeks: arm A, B, or open-label C, 150 µg glucagon alone.
The patients, in real-world settings, performed their usual aerobic exercise with moderate to high intensity for 30 to 75 min. Data analysis was done for the level 1 hypoglycemia incidence based on self-monitoring blood glucose and several exploratory and secondary endpoints.
The authors reported the following findings:
- Forty-five continued to the outpatient phase out of 48 participants who completed the training phase.
- Level 1 hypoglycemia incidence for all exercise sessions in the outpatient phase (n = 795) was lower in both glucagon arms (A, 12%; C, 16%) versus the placebo arm (B, 39%).
- Among treatment arms, times in range, below range, and above range from 0 to 300 min did not remarkably differ.
- With glucagon use, consumed grams of exercise carbohydrates were lower than placebo but did not reach statistical significance.
- Adverse events were comparable among treatment arms.
"In adults with type 1 diabetes, mini-dose glucagon with or without a 50% reduction in CSII basal delivery rate may help to decrease the incidence of exercise-associated hypoglycemia," the researchers concluded.
Reference:
Ronnie Aronson, Michael C. Riddell, Valentina Conoscenti, M. Khaled Junaidi; Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care 2023; dc221145. https://doi.org/10.2337/dc22-1145
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.